Advanced Filters
noise

Camberwell, Australia Clinical Trials

A listing of Camberwell, Australia clinical trials actively recruiting patients volunteers.

Found 542 clinical trials

A Study of Avoralstat In Participants With Diabetic Macular Edema

The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.

18 years of age All Phase 1

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

65 - 130 years of age All Phase 3

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (type …

18 years of age All Phase 1

SNV4818 in Participants With Advanced Solid Tumors

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

18 years of age All Phase 1
K Katherine Gunn

First-In-Human Study to Evaluate Single Ascending Doses of JUV-161 in Healthy Adult Volunteers

The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates. Data from this study …

18 - 60 years of age All Phase 1

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or …

18 years of age All Phase 2
R Rory McCoy

A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM

Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.

22 years of age All Phase N/A
N Nucleus Network, Melbourne

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PN-881 in healthy adult participants.

18 - 65 years of age All Phase 1
C Chris Levi, Professor

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS. Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the …

18 years of age All Phase 2

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11, an anti-CD93 monoclonal antibody, as a monotherapy and in combination in patients with advanced or metastatic solid tumors.

18 years of age All Phase 1

Simplify language using AI